ServiceMaster Global Shares Rally

ServiceMaster Global Shares Rally

ServiceMaster Global Holdings shares rallied to a new record high after resuming trade on Wednesday morning after the company said it plans to spin-off its American Home Shield business from its Terminix and Franchise Services Group businesses.American Home Shield provides home warranties covering the repair and replacement of home systems, components and appliances. The business had revenues of $1.02 billion in 2016. The transaction is expected to be completed in […]

Read More ˃
Icad Reports Positive Study Results

Icad Reports Positive Study Results

Icad developer of cancer treatments, Wednesday reported positive results of a matched-pair cohort study of 369 early-stage non-melanoma skin cancer patients treated with the company’s Xoft Axxent electronic brachytherapy system (x-rays applied to skin cancer sites) or the Mohs micrographic surgery. The study found that rates of recurrence of cancer were virtually identical. The study results were published online in the peer-reviewed Journal of Contemporary Brachytherapy. Icad said Mohs micrographic […]

Read More ˃
VirnetX Holding Corp Enters into Stock Purchase Agreement

VirnetX Holding Corp Enters into Stock Purchase Agreement

In a regulatory filing with the U.S. Securities and Exchange Commission Friday, VirnetX Holding Corp (VHC) disclosed it has entered into a definitive agreement to issue and sell approximately 5.5 million shares of common stock to Public Intelligence Technology Associates for $3.64 per share. This is a 21% discount from Friday’s closing price. The investor recently informed the company that the closing date of the share purchase agreement will not […]

Read More ˃
Halozyme Therapeutics Starts Trial of PEGPH20

Halozyme Therapeutics Starts Trial of PEGPH20

Halozyme Therapeutics shares were up almost 1% pre-market Thursday after the company said it has initiated a multi-arm clinical trial evaluating PEGPH20 in combination with atezolizumab, an anti-PDL1 cancer immunotherapy from Genentech. The combination will be tested in patients with previously treated metastatic pancreatic ductal adenocarcinoma. The study is sponsored and funded by Genentech. The study is part of a clinical collaboration agreement announced by the companies last year to […]

Read More ˃
Achillion Pharmaceuticals’ Chief Scientific Officer Resigns

Achillion Pharmaceuticals’ Chief Scientific Officer Resigns

Achillion Pharmaceuticals reported Tuesday that Joel Barrish, chief scientific officer, plans to leave the company for personal reasons, effective July 14. There are no plans to seek a replacement for his position at this time. In addition, the company said Mingjun Huang is being promoted to senior vice president and head of research. Achillion also said it is continuing to dose paroxysmal nocturnal hemoglobinuria (PNH) patients in a phase 2 […]

Read More ˃